Alzheimer’s disease (AD) is a
neurodegenerative disorder characterized by abnormal
accumulation of amyloid (A) peptide in brain regions subserving memory and
other cognitive functions. Hyperglycemia and perturbed insulin signaling have
been proposed as pathogenic factors contributing to AD. The aim of the present
study is to validate the use of streptozotocin (STZ) injected rats as an
experimental model of AD. Using this model, the effect of intranasal
administration of insulin on reduction of Aß levels was measured. The current
findings strengthen the case for insulin as therapy for AD afflicted
individuals with or without diabetes.